original articlesbreast tumoursQuality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
breast tumours
Under a Creative Commons license
open access
Key words
endocrine resistance
palbociclib
patient-reported outcomes
breast cancer
quality of life
Cited by (0)
Copyright © 2016 THE AUTHORS. Published by Elsevier Ltd.